Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Prelaj A, et al. Transl Lung Cancer Res. 2020 Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. Transl Lung Cancer Res. 2020. PMID: 32676324 Free PMC article.
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. Prelaj A, et al. Cancers (Basel). 2019 Dec 5;11(12):1954. doi: 10.3390/cancers11121954. Cancers (Basel). 2019. PMID: 31817541 Free PMC article.
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. Prelaj A, et al. Clin Lung Cancer. 2020 Sep;21(5):e337-e348. doi: 10.1016/j.cllc.2020.01.005. Epub 2020 Mar 7. Clin Lung Cancer. 2020. PMID: 32291212 Free article.
SMO mutations confer poor prognosis in malignant pleural mesothelioma.
Signorelli D, Proto C, Botta L, Trama A, Tiseo M, Pasello G, Lo Russo G, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, Galli G, De Toma A, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. Signorelli D, et al. Among authors: prelaj a. Transl Lung Cancer Res. 2020 Oct;9(5):1940-1951. doi: 10.21037/tlcr-19-425. Transl Lung Cancer Res. 2020. PMID: 33209614 Free PMC article.
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Lobefaro R, et al. Among authors: prelaj a. Lung Cancer. 2021 Feb;152:165-173. doi: 10.1016/j.lungcan.2020.12.027. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33421923
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Manglaviti S, et al. Among authors: prelaj a. Clin Lung Cancer. 2022 Jan;23(1):e17-e28. doi: 10.1016/j.cllc.2021.06.013. Epub 2021 Jul 5. Clin Lung Cancer. 2022. PMID: 34334296
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Galli G, Corsetto PA, Proto C, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Galli G, et al. Among authors: prelaj a. Clin Lung Cancer. 2022 Nov;23(7):e489-e499. doi: 10.1016/j.cllc.2022.07.010. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 35948460
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Nichetti F, et al. Among authors: prelaj a. Cancers (Basel). 2019 Dec 25;12(1):67. doi: 10.3390/cancers12010067. Cancers (Basel). 2019. PMID: 31881699 Free PMC article.
73 results